HTG Molecular Diagnostics Files For IPO

Tucson, Arizona-based HTG Molecular Diagnostics filed for an IPO over the holidays, saying that it is looking to raise up to $60M on the markets. The company has applied to list as HTGM on the NASDAQ Global Market. HTG Molecular Diagnostics is venture backed by Novo A/S, S.R. One Limited, Merck Capital Ventures, Fletcher Spaght Ventures, Solstice Capital, Valley Ventures, and others. The IPO is being underwritten by Leerink Partners, Canaccord Genuity, and JMP Securities. HTG develops an automated platform used for complex molecular profiling.